تحميل...
Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Russo |
| منشور في: |
ABV-press
2021-09-01
|
| سلاسل: | Opuholi Ženskoj Reproduktivnoj Sistemy |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ojrs.abvpress.ru/ojrs/article/view/845 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|